Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson SA, Mahaffey KW, Neal B, Agarwal R, Bakris G, Perkovic V, Solomon SD, Vaduganathan M. Neuen BL, et al. Among authors: arnott c. Circulation. 2024 Feb 6;149(6):450-462. doi: 10.1161/CIRCULATIONAHA.123.067584. Epub 2023 Nov 12. Circulation. 2024. PMID: 37952217
Characterisation of novel cytokines in human atherosclerotic plaque.
Xia Q, Kahramanian A, Arnott C, Bao S, Patel S. Xia Q, et al. Among authors: arnott c. Int J Cardiol. 2014 Oct 20;176(3):1167-9. doi: 10.1016/j.ijcard.2014.07.252. Epub 2014 Aug 4. Int J Cardiol. 2014. PMID: 25129281 No abstract available.
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ. Neuen BL, et al. Among authors: arnott c. Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5. Lancet Diabetes Endocrinol. 2019. PMID: 31495651
Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China.
Xia S, Du X, Guo L, Du J, Arnott C, Lam CSP, Huffman MD, Arima H, Yuan Y, Zheng Y, Wu S, Guang X, Zhou X, Lin H, Cheng X, Anderson CS, Dong J, Ma C. Xia S, et al. Among authors: arnott c. Circulation. 2020 Feb 18;141(7):530-539. doi: 10.1161/CIRCULATIONAHA.119.043731. Epub 2020 Feb 17. Circulation. 2020. PMID: 32065775 Clinical Trial.
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
Arnott C, Neuen BL, Heerspink HJL, Figtree GA, Kosiborod M, Lam CS, Cannon CP, Rosenthal N, Shaw W, Mahaffey KW, Jardine MJ, Perkovic V, Neal B. Arnott C, et al. Int J Cardiol. 2020 Nov 1;318:126-129. doi: 10.1016/j.ijcard.2020.06.011. Epub 2020 Jun 20. Int J Cardiol. 2020. PMID: 32569700 Clinical Trial.
126 results